Panmure Liberum appointed as Joint Broker to Avacta Group plc

Avacta Therapeutics is a clinical-stage life sciences company focused on improving healthcare outcomes through targeted cancer treatments. The Group is expanding the reach of highly potent cancer therapies with the pre|CISION® platform which is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Avacta’s pipeline consists of pre|CISION® peptide drug conjugates (PDC) and Affimer® drug conjugates (AffDC) that leverage the tumor-specific pre|CISION release mechanism, providing unique benefits over traditional antibody drug conjugates.

Panmure Liberum Team:

Exco – Bidhi Bhoma

Investment Banking – Emma Earl, Will Goode, Mark Rogers

Research – Julie Simmonds

Sales – David Cox

Investor Relations – Jodi Hutchins